MULTIDRUG-RESISTANT POLYMICROBIAL BACTEREMIA AND SEPSIS: A RARE CASE REPORT by Shahbazi Nia, Siavash et al.
Vol 11, Issue 9, 2018
Online - 2455-3891 
Print - 0974-2441
MULTIDRUG-RESISTANT POLYMICROBIAL BACTEREMIA AND SEPSIS: A RARE CASE REPORT
SIAVASH SHAHBAZI NIA1*, SHADAN MODARESAHMADI1, VITHYA THIRUMOORTHI1, QAISAR ANWAR2,  
SHANKAR PRASAD2
1Department of Pharmacy Practice, Al-Ameen College of Pharmacy, Bengaluru, Karnataka, India. 2Department of General Medicine,  
St. Philomena’s Hospital, Bengaluru, Karnataka, India. Email: siavashshahbazinia6640@gmail.com
Received: 27 April 2018, Revised and Accepted: 24 May 2018
ABSTRACT
Antibiotic-resistance is currently a serious threatening factor to global public health that needs a universal action by all government sectors and 
societies. Here, we report an aggressive case of multidrug-resistant (MDR) polymicrobial bacteremia and sepsis. A 73-year-old male patient was 
admitted to a tertiary hospital with the complaints of breathlessness, cough with expectorations, vomiting, loose stools, and altered sensorium due 
to polymicrobial bacteremia and sepsis, which was found to be antibiotic resistant. Blood culture reports showed Pseudomonas aeruginosa and 
Pseudomonas putida, and sputum culture showed Acinetobacter baumannii and Klebsiella pneumonia. However, according to the culture sensitivity test 
reports, the organisms were resistant to almost all antibiotics and different antibiotics were tried. On the last day of hospitalization, the patient started 
desaturation and developed bradycardia and after sometimes cardiac arrest. In spite of continuous cardiopulmonary resuscitation, the patient could 
not be resuscitated and declared to be dead. The patient was finally diagnosed with MDR polymicrobial bacteremia and sepsis, chronic obstructive 
pulmonary disease with cor pulmonale, colitis, diabetes mellitus, hypertension, and respiratory acidosis. Although polymicrobial bacteremia and 
sepsis are rare, awareness of such conditions and of the rare causative pathogens, such as A. baumannii, especially in patients with comorbidities, will 
help treat the patients with bacteremia and sepsis.
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INTRODUCTION
Antimicrobial resistance is a modern warfare against the numerous 
numbers of microorganisms, which are constantly evolving [1]. In the 
last decade, a remarkable increase has been observed in proportion as 
well as in the number of bacterial pathogens exhibiting resistance to 
antibacterial agents. The United States Centers for Disease Control and 
Prevention (USCDC) and the World Health Organization consider the 
infection caused by resistant bacteria as an emergent global disease and 
a major public health problem [2]. From the time when sulfonamide 
and penicillin were introduced into clinical use in the 1930s and 1940s, 
respectively, people were captured by the illusion that all infectious 
diseases could be totally controlled by antibiotics [3]. This was while 
the prolonged and repeated courses of antibiotics exposure were 
compelling the development of antibiotic-resistant organisms [4].
Universal, rapid appearance of resistant bacteria endangers the 
efficacy of antibiotics, which have considerably saved millions of lives. 
In 1945, Sir Alexander Fleming raised the alarm regarding antibiotic 
overuse, which clearly drives the evolution of resistance [5]. Infection 
with antibiotic-resistant bacteria may lead to severe illness, increased 
mortality rates, and an increased risk of complications and admission 
to hospital [6]. Failure to apply infection control measures in a hospital 
and outside it can be an important cause for the spread of antibiotic 
resistance [7]. Infections caused by multidrug-resistant (MDR) 
organisms can cause consequential economic burden, estimated to be 
more than 20 billion dollars per year in the United States of America 
(USA) only. The USCDC reports that more than 23,000 people in the 
USA are dying per year due to an infection with an antibiotic-resistant 
organism. Moreover, it anticipates that antibiotic resistance can cause 
300 million premature deaths by 2050, with a global economic loss 
up to $100 trillion [8]. Antibiotic resistance is a global concern since 
new resistance mechanisms are appearing and spreading globally, 
minimizing our ability to treat common infectious diseases, thereby 
leading to prolonged illness, disability, and death [9]. Hence, hereby, we 
report a 73-year-old male patient with the complaints of breathlessness, 
cough with expectorations, vomiting, loose stools, and altered 
sensorium due to rare condition of MDR polymicrobial bacteremia and 
sepsis caused by rare pathogens, such as Acinetobacter baumannii so as 
to make an awareness regarding jeopardy of antibiotic-resistance and 
its consequences [10,11].
CASE REPORT
A 73-year-old male patient was admitted to a tertiary care hospital with 
the presenting complaints of breathlessness, cough with expectorations, 
vomiting, loose stools, and altered sensorium. Hence, he was shifted 
to the Intensive Care Unit. The patient also developed abdominal 
distention and did not pass stools since the time of admission.
The patient had a history of chronic obstructive pulmonary disease 
(COPD) with cor pulmonale, diabetes mellitus, and hypertension. He 
was admitted to the hospital, twice earlier for exacerbation of COPD 
and bilateral lower lobe pneumonia. His first admission was in January 
2016, and he was hospitalized for a period of 6 days. His second 
admission was on August 2016, and he was hospitalized for 8 days.
According to the patient’s history, he was apparently fine until 3 days 
before the admission when he developed breathlessness and cough 
with expectorations, which was yellowish in color, vomiting 3–4 
episodes, and loose stools 4–5 times.
On admission (December 2016), blood pressure (BP) was found to be 
120/80 mmHg, pulse rate was 102 bpm, general random blood sugar 
was 110 mg/dl, respiratory rate was 22 bpm, O2 saturation was 86% in 
room air, and temperature was 98.6° F. Complete blood count results 
showed elevated white blood cell (WBC) and neutrophil level. The 
patient was prescribed with intravenous amoxicillin-clavulanate thrice 
a day, tablet amlodipine twice a day, tablet rosuvastatin once a day, 
tablet sildenafil twice a day, nebulizer ipratropium bromide-salbutamol 
thrice a day, and nebulizer budesonide thrice a day. Insulin therapy was 
also started for the patient to control his blood glucose level.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i9.26965
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On day 2, the patient became drowsy, and he was not obeying 
commands. Arterial blood gas report showed elevated pCo2. The chest 
X-ray results showed bilateral lower lobe haziness. As the patient’s 
WBC count has increased, the physician considered the previous 
antibiotic to be ineffective and stopped it. Simultaneously, he started 
intravenous levofloxacin once a day and continued the remaining 
treatment. In addition, the blood sample was sent for susceptibility 
analysis.
On day 3, the patient still had cough with expectoration and 
breathlessness. He developed abdominal distension, and his BP was 
raised to 140/90 mmHg. Electrocardiography also showed sinus 
tachycardia. The physician added intravenous cefoperazone-sulbactam 
twice a day, intravenous metronidazole thrice a day, and intravenous 
pantoprazole once a day and continued the remaining medicines.
On day 4, the patient became drowsier, and his BP was raised to 
170/110 mmHg. He was febrile, and WBC count was almost same. 
The physician substituted intravenous cefoperazone-sulbactam 
with intravenous meropenem thrice a day. The patient was also 
prescribed with intravenous enoxaparin twice a day and intravenous 
paracetamol thrice a day, infusion fentanyl and remaining medicines 
were continued. Moreover, the patient had been put on ventilator 
support and undergone exploratory laparoscopy due to his abdominal 
distention. From the exploratory laparoscopy, it was found that a 
segment of jejunum about 15 cm in length, starting 10 cm from the 
duodenal-jejunal junction, was congested and thickened. Moreover, 
exploratory laparoscopy showed good peristaltic activity, and there 
was no evidence of necrotic patches.
On day 5, 6, 7, and 8 of hospitalization, the patient had fever spike (105° 
F), and WBC count had reduced. However, on day 6 of hospitalization, 
blood culture reports showed Pseudomonas putida to be present. 
Susceptibility information for P. putida is presented in Table 1.
On day 9, the patient was trying to open his eyes, and he was responding 
to verbal commands. The physician advised physiotherapy.
On day 10, still, the patient was responding to verbal commands. His WBC 
count had drastically elevated up to 40000 cells/cumm. In addition, the 
neutrophil level also increased to 91%. Hence, the physician stopped 
intravenous levofloxacin and added intravenous fluconazole once a 
day and intravenous clindamycin thrice a day. In addition, blood and 
sputum samples were sent for susceptibility analysis.
On day 11, still, the patient had fever spikes. The patient was given 
intravenous amikacin twice a day.
On day 12, 13, and 14, the patient opened his eyes to commands. 
The patient was febrile and his BP was normal. WBC count, as well 
as neutrophil level, was still high. On day 14 of hospitalization, blood 
culture reports showed Pseudomonas aeruginosa, and sputum culture 
showed A. baumannii to be present. Same medication had been 
continued during these 3 days. On Table 2, susceptibility information 
for P. aeruginosa, and on Table 3, susceptibility information for 
A. baumannii can be observed.
On day 15, the patient’s BP was 150/80 mmHg. He was still febrile. 
His WBC count and neutrophil level have decreased. However, sputum 
culture showed Klebsiella pneumonia to be present. The physician 
stopped intravenous meropenem and started intravenous doxycycline 
twice a day and intravenous colistin twice a day. Table 4 represents the 
susceptibility information for K. pneumonia.
On day 16, the patient had elevated BP. The physician stopped 
intravenous amikacin and intravenous fluconazole.
On day 17, the patient was febrile, conscious and he had nasal bleeding. 
Ear-nose-throat (ENT) specialist opinion sought and tracheostomy was 
done since the patient was on prolonged ventilation.
On day 18, abdominal distension was still present, and the patient 
developed bilateral pedal edema. His WBC count started to increase. 
Intravenous colistin and intravenous clindamycin were stopped, and 
intravenous tigecycline twice a day was started.
On day 19, the patient had a very poor general condition. His BP was 
90/40 mmHg. Despite the patient had received different antibiotics, 
his condition did not change. Hence, the physician shifted the patient 
to the isolation room. The patient started desaturation and developed 
bradycardia. Hence, 1 ampule atropine was given, but the patient 
developed cardiac arrest. In spite of continuous cardiopulmonary 
resuscitation and administering adrenaline, the patient could not be 
resuscitated and declared to be dead.
According to the susceptibility analysis reports presented in Tables 1-4, 
different antibiotics were tried. In addition to antibiotics, antifungal, 
diuretic, heparin, parenteral nutrition, analgesic, antacid, and other 
supportive measures were used during his stay of 19 days in the 
hospital. His final diagnosis was MDR polymicrobial bacteremia and 
sepsis, COPD with cor pulmonale, lower respiratory tract infection, 
colitis, diabetes mellitus, and hypertension.
DISCUSSION
Antibiotic resistance is one of the biggest threats to global health, which 
can affect anyone, of any age, in any country. Antibiotic resistance 
occurs naturally, but misuse of antibiotics in humans and animals is 
accelerating the process [10].
In the aforementioned case, we are observing a rare condition of 
MDR polymicrobial bacteremia and sepsis, which had been caused 
by multiple pathogens, namely, P. aeruginosa, P. putida, A. baumannii, 
and K. pneumonia among which A. baumannii is a rare causative 
organism[10,11].
In this case, rational use of antibiotics can be observed to some extent. 
In other words, only a few numbers of antibiotics were prescribed or 
substituted with other agents based on culture reports. However, the 
majority of changes in antibiotic therapy were based on changes in 
WBC and neutrophil counts or persistence of fever in the patient. In 
the 1st day of admission, as past history of the patient was not fully 
known, based on the general rule for the treatment of infectious 
diseases, a broad-spectrum antibiotic (amoxicillin-clavulanate) had 
been prescribed to the patient until the exact pathogens were known 
[12]. After the patient’s history was understood, as he had two previous 
admissions for pneumonia and COPD, amoxicillin-clavulanate was 
considered to be ineffective and therefore substituted with levofloxacin. 
In addition, the increment in WBC count was also influential in taking 
decision for this change of antibiotic. On the 3rd day of admission, 
cefoperazone-sulbactam and metronidazole were added to the 
patient’s prescription. However, on the 4th day of admission, due to the 
high and constant value of WBC count, cefoperazone-sulbactam had 
been substituted with meropenem as it is a broad-spectrum antibiotic 
and covers the majority of gram-negative and gram-positive organisms. 
On day 6 of hospitalization, blood culture reports showed P. putida 
(Table 1) to be present, and it was found that P. putida was resistant to 
the majority of antibiotics. As on the 10th day of admission, the patient’s 
condition had been worsened, and the physician stopped levofloxacin. 
As in the culture report, the sensitivity of P. putida to clindamycin 
had not been checked, and there were chances of sensitiveness of P. 
putida to this antibiotic. Hence, physician started this antibiotic and 
also added fluconazole for prophylactic purposes. On the 11th day of 
hospitalization, still the patient had fever spike, and his condition 
did not improve. Hence, he was suspected to be infected by some 
other organisms. As a result, amikacin was started empirically. On 
the 14th day of hospitalization, WBC count, as well as neutrophil level, 
was still high. Blood culture reports showed P. aeruginosa (Table 2) 
and sputum culture showed A. baumannii (Table 3) to be present and 
both were found to be sensitive to colistin. Hence, colistin was started. 
On the next day, from sputum culture, it was found that K. pneumonia 
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(Table 4) sensitive to tetracyclines was present. As a result, doxycycline 
was prescribed to the patient. On the 18th day of admission, since the 
patient’s condition started worsening, tigecycline was also prescribed 
to get benefit from its synergistic effect with doxycycline. However, 
unfortunately, none of these many antibiotics were effective against the 
microorganisms infected the patient.
In general, management of antibiotic resistance is an attempt to slow 
the spread of resistance through prudent use of antibiotics based 
on guidelines of antimicrobial stewardship programs and various 
data such as pharmacokinetic and pharmacodynamic properties of 
antibiotics, diagnostic testing, antimicrobial susceptibility testing, 
clinical response, and effects on the microbiota, as well as by new 
antibiotic developments. Evolution of antibiotic resistance can be 
slowed by minimizing the antibiotic use and avoidance from treating 
asymptomatic infections. Antibiotics must be used only if they are 
considered to be effective and when treatment is essential as little 
antibiotic as possible must be used. Moreover, through use of vaccines, 
Table 1: Susceptibility information for Pseudomonas putida performed on day 6
Antibiotic Interpretation Antibiotic Interpretation
Amoxicillin/Clavulanate R Ciprofloxacin R
Ampicillin R Tigecycline R
Ceftriaxone R Nitrofurantoin R
Cefuroxime R Nalidixic acid R
Cefuroxime axetil R Meropenem R
Cefepime R Imipenem R
Cefoperazone/Sulbactam R Ertapenem -
Piperacillin/Tazobactam R Colistin S
Gentamicin R Trimethoprim/Sulfamethoxazole R
Amikacin R - -
Levofloxacin R - -
S: Sensitive, R: Resistant
Table 2: Susceptibility information for Pseudomonas aeruginosa performed on day 14
Antibiotic Interpretation Antibiotic Interpretation
Ceftazidime R Minocycline R
Cefepime R Tigecycline R
Cefoperazone/Sulbactam R Meropenem R
Piperacillin/Tazobactam R Doripenem R
Ticarcillin/Clavulanate R Imipenem R
Gentamicin R Aztreonam R
Amikacin R Colistin S
Ciprofloxacin R Trimethoprim/Sulfamethoxazole R
Levofloxacin R - -
S: Sensitive, R: Resistant
Table 3: Susceptibility information for Acinetobacter baumannii performed on day 14
Antibiotic Interpretation Antibiotic Interpretation
Ceftazidime R Minocycline R
Cefepime R Tigecycline R
Cefoperazone/Sulbactam S Meropenem R
Piperacillin/Tazobactam R Doripenem R
Ticarcillin/Clavulanate - Imipenem R
Gentamicin R Aztreonam R
Amikacin - Colistin S
Ciprofloxacin R Trimethoprim/Sulfamethoxazole R
Levofloxacin R - -
S: Sensitive, R: Resistant
Table 4: Susceptibility information for Klebsiella pneumonia performed on day 15
Antibiotic Interpretation Antibiotic Interpretation
Amoxicillin R Amikacin R
Amoxicillin/clavulanate R Ciprofloxacin R
Ampicillin R Tigecycline I
Ceftriaxone R Nitrofurantoin R
Cefotaxime R Nalidixic acid R
Cefuroxime R Meropenem R
Cefuroxime axetil R Imipenem R
Cefepime R Ertapenem R
Cefoperazone/Sulbactam R Colistin R
Piperacillin/Tazobactam R Trimethoprim/Sulfamethoxazole R
Gentamicin R - -
R: Resistant, I: Intermediate
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hygiene, and isolation of infected patients, the need for antibiotic 
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